erymethionase / eryminase
|Product Candidate / PROGRAM||Drug substance||Indication||Discovery||Pre-clinical||Phase 1||Phase 2||Phase 3/ Pivotal||EMA/FDA review||Commercial Rights|
|eryminase||Arginine deiminase||Solid tumors|
In addition to L-asparaginase, the active ingredient in our lead product candidate eryaspase, we are leveraging our proprietary ERYCAPS technology to develop additional product candidates, encapsulating other therapeutic drug substances. Based on our preclinical research, we have identified two other Cancer Metabolism enzymes, methionine-γ-liase (MGL) and arginine deiminase (ADI), which we believe can benefit from being encapsulated in red blood cells. MGL and ADI degrade methionine and arginine respectively, two amino acids that are essential for tumor cells to survive and grow. erymethionase is currently in the end of preclinical development.